Clinical Trials
788 trialsTesting the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
CaDAnCe-101
BeOne Medicines
MAHOGANY
BeOne Medicines
HEMO-CONNECT
Centre Hospitalier de la côte Basque
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
City of Hope Medical Center
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
BAF_FRontier-1
Eli Lilly and Company
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage â… -â…¡ MALT Lymphoma
Zhejiang Cancer Hospital
Obinutuzumab in Marginal Zone Lymphoma
University of Ulm
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
University of Ulm
OLYMPIA-5
Regeneron Pharmaceuticals
EPCOREâ„¢ NHL-1
Genmab
EPCOREâ„¢ NHL-3
Genmab
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
LYMFOR
Pentixapharm AG
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Seoul National University Hospital
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
New York Medical College
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
MALIBU
International Extranodal Lymphoma Study Group (IELSG)
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
Study of Acalabrutinib and Tafasitamab in MZL Patients
International Extranodal Lymphoma Study Group (IELSG)
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
CLOVER-WaM
Cellectar Biosciences, Inc.
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Archonc-001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Dana-Farber Cancer Institute
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Massachusetts General Hospital
Atalanta-1
Lakefront Biotherapeutics NV
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Beth Israel Deaconess Medical Center
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago